High quality Research and Development (R&D) efforts are the backbone of any successful pharmaceutical company. Growing requirements in respect of the quality of our products necessitate large investments in R&D. Our efforts are in particular focused on producing highly effective and safe medicines.
Large investments are required to deliver highly differentiated innovative products that address significant unmet medical need. Our efforts are indeed focused on bringing to the market medicines that really matter to people
Our main areas of research
Discovering new medicines
Our R&D teams are dedicated to delivering medicines that have a positive effect on the lives of patients. Our focus area are gastroenterology, osteoporosis, respiratory, pain and tissue management. Our expertise in these areas enables us to develop new medicines with partner companies, as well as conduct our own research. In addition to the in-house expertise in the TA/indication areas our R&D model relies significantly on realistic partnerships. This is very evident in our current R&D pipeline.
Putting patient safety first and delivering product with highly favorable therapeutic index.
We diligently test our products, conducting clinical trials to evaluate the safety and efficacy of each new product. We are committed to conducting new and ongoing clinical trials with new products, and to disclosing study results as appropriate in free public repositories.
The research phases
Discovery & Development of new medicines takes a long time – often more than ten years. At every point of screening & development, human safety is always primary . The products must prove safety and efficacy at each stage until registration.
-
Discovery actively looks for new targets that can treat indication of choice. Compounds are screened in vitro and in vivo assays to identity hits that can be optimized as clinical candidates
-
Clinical trials begin clinical investigation of the medicine in humans. Initial development studies are usually performed using healthy volunteers to ascertain tolerability, safety and uptake and secretion of the medicine. (Phase 1 – Phase 3)
-
Registration involves compiling data for registration and assisting the authorities to analyse the information and give necessary approval to marketing the drug.
High-technology departments
Research in different target / indication areas are also supported by high-technology departments which provide general services to expedite the overall process. These technologies are in the areas of chemo-and bioinformatics, combinatorial chemistry, high-throughput screening, biotechnology and protein technologies.